{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:57:24Z","timestamp":1776499044059,"version":"3.51.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We compared outcomes of four different management modalities for diabetic VH. Patients with diabetic VH were identified in this retrospective study undertaken at King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Eyes were grouped based on the treatment received: control (observation only), intravitreal bevacizumab (IVB) injection(s), pars plana vitrectomy (PPV), and preoperative single IVB injection before PPV. Best-corrected visual acuity (BCVA) and status of VH were noted at baseline and the last follow up (Minimum: 6 months, maximum: 29 months). The proportion of eyes with Snellen BCVA improvement by two lines or more and VH clearance at the last follow up were compared between groups. The four groups \u2013 Control, IVB, PPV, and IVB-before-PPV had 23, 29, 17, and 20 eyes, respectively. The proportion of eyes gaining \u22652 lines was substantially higher in the IVB-before-PPV and PPV groups (90% and 77%, respectively) compared with IVB and observation groups (41% and 22%, respectively). Surgical treatment was associated with a 2.38 times higher likelihood of gaining \u22652 lines than the non-surgical one (incidence ratio: 2.38, 95% CI 1.19, 4.78\u2009<jats:italic>P<\/jats:italic>\u2009=\u20090.015) after adjusting for age, hyperglycemia and BCVA at presentation. Less invasive treatment such as IVB injections did not result in the same amount of improvement in vision as did PPV. Prospective randomized studies are needed to better define the role of IVB injections in the management of diabetic VH.<\/jats:p>","DOI":"10.1038\/s41598-020-60378-8","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T11:02:41Z","timestamp":1582887761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of outcomes of four different treatment modalities for diabetic vitreous haemorrhage"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0301-6000","authenticated-orcid":false,"given":"Ibrahim","family":"Taskintuna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maram E. A. Abdalla","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaan","family":"Taskintuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khabir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1747-0928","authenticated-orcid":false,"given":"Patrik","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"issue":"13","key":"60378_CR1","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti, D. A., Klein, R. & Gardner, T. W. Diabetic Retinopathy. N Engl J Med 366(13), 1227\u20131239 (2012).","journal-title":"N Engl J Med"},{"key":"60378_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1001\/archopht.1974.01010010307006","volume":"92","author":"PH Morse","year":"1974","unstructured":"Morse, P. H., Aminiari, A. & Scheie, H. G. Spontaneous vitreous haemorrhage. Arch Ophthalmol 92, 297\u2013298 (1974).","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"60378_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","volume":"88","author":"Diabetic Retinopathy Study Research Group","year":"1981","unstructured":"Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology 88(7), 583\u2013600 (1981).","journal-title":"Ophthalmology"},{"issue":"10085","key":"60378_CR4","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","volume":"389","author":"S SIVBprasad","year":"2017","unstructured":"SIVBprasad, S. et al. on behalf of the CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 389(10085), 2193\u2013203 (2017).","journal-title":"Lancet"},{"issue":"20","key":"60378_CR5","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"JG Gross","year":"2015","unstructured":"Gross, J. G. et al. and Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA 314(20), 2137\u201346 (2015).","journal-title":"JAMA"},{"issue":"9","key":"60378_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0161-6420(92)31779-8","volume":"99","author":"HW Flynn","year":"1992","unstructured":"Flynn, H. W. et al. The Early Treatment Diabetic Retinopathy Study Research Group. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study: ETDRS report number 17. Ophthalmology 99(9), 1351\u20131357 (1992).","journal-title":"Ophthalmology"},{"key":"60378_CR7","doi-asserted-by":"crossref","unstructured":"Yanoff, M. & Duker, J. S. Vitrectomy. In: Ophthalmology. 3rd ed. St Louis, M.O.: Mosby Elsevier 533 (1999).","DOI":"10.1097\/00006982-199903000-00022"},{"issue":"3","key":"60378_CR8","first-page":"283","volume":"131","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous haemorrhage from proliferatve diabetic retinopathy. JAMA Ophthalmol 131(3), 283\u201393 (2015).","journal-title":"JAMA Ophthalmol"},{"key":"60378_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide, R. F. & Fisher, Y. L. Intravitreal bevacizumab (avastin) treatment of proliferative diabetic retinopathy complicated by vitreous haemorrhage. Retina 26, 275\u20138 (2006).","journal-title":"Retina"},{"key":"60378_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2017.01.010","volume":"176","author":"RN Parikh","year":"2017","unstructured":"Parikh, R. N. et al. Intravitreal bevacizumab for the treatment of vitreous haemorrhage due to proliferative diabetic retinopathy. Am J. Ophthalmol 176, 194\u2013202 (2017).","journal-title":"Am J. Ophthalmol"},{"issue":"6","key":"60378_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/IAE.0000000000001673","volume":"38","author":"E Chelala","year":"2018","unstructured":"Chelala, E. et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous haemorrhage related to proliferative diabetic retinopathy. Retina 38(6), 1127\u20131133 (2018).","journal-title":"Retina"},{"key":"60378_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","volume":"13","author":"JT Holladay","year":"1997","unstructured":"Holladay, J. T. Proper method for calculating average visual acuity. J. Refract Surg. 13, 388\u201391 (1997).","journal-title":"J. Refract Surg."},{"issue":"4","key":"60378_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0161-6420(80)35232-9","volume":"87","author":"MC Ziemianski","year":"1980","unstructured":"Ziemianski, M. C., McMeel, J. W. & Franks, E. P. Natural history of vitreous haemorrhage in diabetic retinopathy. Ophthalmology 87(4), 306\u201312 (1980).","journal-title":"Ophthalmology"},{"issue":"1","key":"60378_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamaophthalmol.2015.4587","volume":"134","author":"TL Jackson","year":"2016","unstructured":"Jackson, T. L. et al. The Royal College of Ophthalmologists\u2019 National Ophthalmology Database Study of Vitreoretinal Surgery Report 6, Diabetic Vitrectomy. JAMA Ophthalmol 134(1), 79\u201385 (2016).","journal-title":"JAMA Ophthalmol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60378-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:29:19Z","timestamp":1670311759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60378-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60378"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60378-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3674"}}